Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sara Mosaffa"'
Autor:
Katherine Klein, Kewen He, Ahmed I. Younes, Hampartsoum B. Barsoumian, Dawei Chen, Tugce Ozgen, Sara Mosaffa, Roshal R. Patel, Meidi Gu, Jose Novaes, Aarthi Narayanan, Maria Angelica Cortez, James W. Welsh
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The role of mitochondria in cancer formation and progression has been studied extensively, but much remains to be understood about this complex relationship. Mitochondria regulate many processes that are known to be altered in cancer cells, from meta
Externí odkaz:
https://doaj.org/article/3d3575ff14284a47b2bbc868d0a42c50
Autor:
James W. Welsh, Maria Angelica Cortez, Katherine Klein, Tugce Ozgen, Sara Mosaffa, Fatemeh Masropour, Mark Wasley, Hari Menon, Yun Hu, Vivek Verma, Ahmed I. Younes, Liangpeng Yang, Hampartsoum B. Barsoumian, Dawei Chen
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f95625e3541384be46a8ffa61c5569c
https://doi.org/10.1158/2326-6066.22543947
https://doi.org/10.1158/2326-6066.22543947
Autor:
James W. Welsh, Maria Angelica Cortez, Katherine Klein, Tugce Ozgen, Sara Mosaffa, Fatemeh Masropour, Mark Wasley, Hari Menon, Yun Hu, Vivek Verma, Ahmed I. Younes, Liangpeng Yang, Hampartsoum B. Barsoumian, Dawei Chen
Immune checkpoint inhibitors, such as anti–PD-1/PD-L1, have emerged as promising therapies for advanced non–small cell lung cancer (NSCLC). However, approximately 80% of patients do not respond to immunotherapy given alone because of intrinsic or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda51812534a46937fc87a65c71cbc67
https://doi.org/10.1158/2326-6066.c.6550473
https://doi.org/10.1158/2326-6066.c.6550473
Autor:
Yun Hu, Maria Angelica Cortez, Sara Mosaffa, Mark Wasley, Hari Menon, Ahmed I. Younes, Tugce Ozgen, Hampartsoum B. Barsoumian, Fatemeh Masropour, L. Yang, Vivek Verma, James W. Welsh, Dawei Chen, Katherine Klein
Publikováno v:
Cancer Immunol Res
Immune checkpoint inhibitors, such as anti–PD-1/PD-L1, have emerged as promising therapies for advanced non–small cell lung cancer (NSCLC). However, approximately 80% of patients do not respond to immunotherapy given alone because of intrinsic or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c76daf653a436a909ada78d815d3f77
https://doi.org/10.1158/2326-6066.cir-19-0744
https://doi.org/10.1158/2326-6066.cir-19-0744
Publikováno v:
Iranian Journal of Pediatrics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d72765abac3c9f9da85600457c97bbd
https://pubmed.ncbi.nlm.nih.gov/23056735
https://pubmed.ncbi.nlm.nih.gov/23056735